【New Delhi】Japanese drug-maker Daiichi Sankyo has said it will help Ranbaxy Laboratories Ltd meet the US Food and Drug Administration's (FDA) norms to overcome sanctions.
Exports of drugs from Ranbaxy's Mohali plant in Punjab to the US were banned in September after the FDA claimed that the facility did not meet quality norms laid down by it.
In a meeting with Commerce and Industry Minister Anand Sharma on Thursday, Daiichi Sankyo's President and CEO George Nakayama said the company will extend technical assistance to help upgrade Ranbaxy's plants in India that have been hit by the US'quality sanctions, a Commerce Ministry official said.
Daiichi, which owns a controlling stake in Ranbaxy, will focus on the company's plant in Mohali.
Daiichi may bring in additional teams of technical experts from Japan to help the former meet quality concerns raised by US FDA.
【News source】